Hunan Sinoland Bio-pharmacy CO.,Ltd announced that it has received CNY 80 million in funding from Tianjin Ringpu Bio-Technology Co.,Ltd.
October 28, 2021
Share
On October 29, 2021, Hunan Sinoland Bio-pharmacy CO.,Ltd closed the transaction. The company amended the terms of the transaction, and received gross proceeds of CNY 80,000,000. Jingpeng Holding Group Co., Ltd did not participate in the transaction. The company entered into a supplement agreement with its shareholders in connection with the transaction. Post closing, the stake of Tianjin Ringpu Bio-Technology Co.,Ltd. in the company increased to 68.4213%, and the registered capital of the company increased to CNY 153,093,565. The company completed the procedures of industrial and commercial change registration and obtained a new business license renewed by the Hunan Provincial Market Supervision Administration. The transaction was approved by shareholders of the company.
TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD is a China-based company principally involved in the research, development, manufacture and sales of biological products and preparations for veterinary uses. The Company operates through two main segments. The Veterinary Use Biological Products segment is mainly involved in the manufacture and sales of poultry vaccines, veterinary use vaccines, biological products for treatment, diagnostic products and other biological products. The Veterinary Preparations segment is mainly involved in the manufacture and sales of chemical preparations, veterinary Chinese medicine and other preparations.